PT  - JOURNAL ARTICLE
AU  - Ha, Edward T.
AU  - Ivanov, Alexander
AU  - Yeoboah, Joseph
AU  - Seals, Austin
AU  - Peterson, Stephen J.
AU  - Parikh, Manish
AU  - Aronow, Wilbert S.
AU  - Frishman, William H.
TI  - Left ventricular hypertrophy subtype and long-term mortality in those with subclinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA)
AID  - 10.1101/2022.01.29.22270084
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.29.22270084
4099  - http://medrxiv.org/content/early/2022/01/31/2022.01.29.22270084.short
4100  - http://medrxiv.org/content/early/2022/01/31/2022.01.29.22270084.full
AB  - The clinical and biochemical profile of differing LVH phenotypes and its effect on long term outcomes is ill-defined. The study investigated the differences in risk profiles and prognostic effect of concentric (CH) and eccentric hypertrophy (EH) on long-term adverse outcomes in a contemporary, ethnically diverse cohort. We analyzed follow-up data over 15 years from the Multi-Ethnic Study of Atherosclerosis study, an ongoing multicenter, prospective population-based study in the United States that enrolled 6,814 participants with subclinical cardiovascular disease between 2000 and 2002. 4,979 participants with left ventricular mass and wall thickness, derived from cardiac MRI at baseline enrollment were included. Descriptive statistics, Kaplan-Meier curves, and regression models were applied. Independent variables associated with CH were Black and Hispanic race/ethnicity, systolic blood pressure, and metabolic syndrome. Independent variables associated with EH were systolic blood pressure, urine creatinine, whereas serum creatinine had an inverse association. The primary endpoint of all-cause death (n=1,137, 22.8%) occurred in 21.7%, 47.4%, and 56.6% of participants with no, concentric, or eccentric hypertrophy, respectively (p<0.001). Age (HR per year = 1.10 [1.09, 1.11], p<0.001), male gender (HR=1.48 [1.29, 1.69], p<0.001), Black race (HR=1.17 [1.005,1.36], p=0.04), fasting glucose (HR=1.005 [1.003, 1.007], p<0.001), baseline creatinine (HR per mg/dL = 1.29 [1.15-1.46], p<0.001), LVEF (HR per 1% = 0.98 [0.98, 0.99], p=0.005), IL-6 (HR per pg/mL = 1.17 [1.12, 1.22], p<0.001), concentric hypertrophy (HR=1.84 [1.41-2.41], p<0.001), and eccentric hypertrophy (HR=2.58 [1.77-3.76], p<0.001) were significant predictors of all-cause mortality. We conclude that CH and EH are two distinct clinical phenotypes of left ventricular hypertrophy with differing gender and racial predisposition, both associated with worse long-term adverse outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MESA study was approved by the institutional review boards of each of the participating field sites in the United States (Wake Forest University, Winston-Salem, NC; Columbia University, New York City, NY; Johns Hopkins University, Baltimore, Md; University of Minnesota, Minneapolis, Minn; Northwestern University, Evanston, Ill; and University of California, Los Angeles, Calif), and all participants provided written informed consent. All sites were compliant with the Health Insurance Portability and Accountability Act. The design of MESA (ClinicalTrials.gov: NCT00005487) has been previously described.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors